Clinical trials: 2019-nCoV
COVID-19, 2019 Novel Coronavirus Infection
Evaluating Clinical Parameters of COVID-19 in Pregnancy
Coronavirus infection, also known as COVID-19, has become a global pandemic with over 3 million cases and 250,000 deaths worldwide.
- Conditions
- COVID-19, 2019 Novel Coronavirus Infection, COVID-19 Infection
- Trial name
- COpregVID (NCT04470583)
- Where
- 2 sites in United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
COVID-19 Vaccines, Autoimmune Diseases
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
According to the comprehensive evaluation, the completion of vaccination and the prevention and treatment strategy of integrated traditional Chinese and western medicine have obvious advantages in improving the symptoms of…
- Trial name
- NCT05831826
- Testing
- the inactivated COVID-19 vaccines
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Chinese Medical University
COVID, Sars-CoV2
Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection
The study was not opened.
- Trial name
- NCT04409184
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
COVID-19
Educational Interventions for Surgeons During COVID-19 Pandemic: Cross-sectional, E-survey
The coronavirus disease 2019 (COVID-19) pandemic required a rapid surge of healthcare capacity to face a growing number of critically ill patients.
- Trial name
- EDUCOVID (NCT04732858)
- Testing
- Cross sectional e-Survey on surgeons exposed to any educational intervention
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19 Vaccine
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The goals of this clinical trial are: 1. Phase 2: to test a gamma adapted recombinant vaccine against SARS-CoV-2 in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. 2.
- Trial name
- ARVAC-F2/3 (NCT05752201)
- Testing
- Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivalent RBD-based ARVAC-CG vaccine
- Where
- 11 sites in Argentina
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Healthy Participant
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
- Trial name
- NCT07235137
- Testing
- Ibuzatrelvir
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2
Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose escalation part (Phase 1 study) followed by an open-label single arm (or two-arms, randomized) dose expansion part (Phase 2 study).
- Conditions
- COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation
- Trial name
- NCT04788459
- Testing
- COVID-eVax, Cliniporator® and EPSGun
- Where
- 4 sites in Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Takis
COVID-19
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
Aerosol Combination therapy of All-trans retinoic acid and Isotretinoin as A novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients better than vaccine : An innovative Treatment Mahmoud…
- Trial name
- Antibodies (NCT04396067)
- Testing
- Aerosolized 13 cis retinoic acid, Aerosolized All trans retinoic acid
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
COVID-19
Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)
The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and…
- Trial name
- NCT04465474
- Testing
- Non Intervention
- Where
- 10 sites in China, Hong Kong and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Coronavirus Disease 2019
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
Popular topic:Clinical trials of the consistency and non-inferiority bridging between batches of recombinant new coronavirus vaccine (CHO cells) Research purpose:Main purpose:1)To evaluate the interbatch consistency of…
- Trial name
- NCT05091411
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19 Vaccine
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
- Trial name
- NCT05656508
- Testing
- ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Covid19
The VIDA After COVID Study
The purpose of this study is to objectively identify and address social determinants of health (SDOH) priorities and barriers in Latino patients who survived or are vulnerable to COVID-19, and to understand the consequences of…
- Trial name
- NCT04945590
- Testing
- Virtual Intervention Program
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mayo Clinic
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, Vaccine Reaction
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
In this phase 1 study, the inactivated virus vaccine National Research Centre (NRC) Vaccine-101 (VACC-101) will be investigated for its safety and immunogenicity in healthy volunteers with the aim of providing effective and safe…
- Conditions
- COVID-19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- NCT05128721
- Testing
- Covi Vax
- Where
- Egypt
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Research Centre, Egypt
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre